MMAE

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
MMAE, Neoplasm, Patient, PST, Yale school, CSPC, Shijiazhuang Pharma Group, Yale School of Medicine, ADC, Rash, Peripheral neuropathy, Brentuximab vedotin, ASCO, MUC, Poster, Society, Cervical cancer, Safety, EV, GU, Corbus, Urology, Tab, Trial of the century, Pharmaceutical industry

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.

Key Points: 
  • The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.
  • The poster will also be available on the Corbus website at the start of the poster presentation.
  • We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."
  • Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Retrieved on: 
Friday, January 12, 2024
MMAE, Woman, FTD, Patient, European, ADC, Tissue, MSLN, Food, Disease, Safety, FDA, EOC, Ovarian cancer

This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.

Key Points: 
  • This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.
  • RC88 consists of a recombinant humanized anti-MSLN monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE), which acts as a microtubule inhibitor.
  • The later the stage and the more aggressive the ovarian cancer, the higher the expression rate of MSLN, and current treatment options are limited.
  • Moving forward, RemeGen will continue to accelerate the development of its ADC products, with the aim of bringing more and better solutions to patients globally."

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Retrieved on: 
Monday, December 18, 2023
CSPC, Conference, AACR, Food, ASCO, Carcinoma, Society, Brentuximab vedotin, Patient, ADC, MMAE

NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) , to be held January 25-27, 2024 in San Francisco, CA and online.

Key Points: 
  • NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) , to be held January 25-27, 2024 in San Francisco, CA and online.
  • CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a third generation, site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload.
  • Pre-clinical data demonstrating differentiation from enfortumab vedotin was recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.

POLIVY (Polatuzumab Vedotin-piiq) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, Pharmaceutical, Health, MMAE, Apoptosis, Research, Immunoglobulin G, ADC, Clinical trial, SWOT, EU4, Microtubule, Polatuzumab vedotin, Roche, CD79B, Cell division, NHL, Fine chemical, Risk management, Vaccine, Pharmaceutical industry, DLBCL

This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

Retrieved on: 
Thursday, December 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MMAE, GMP, Immunogenic cell death, ITF, CDMO, MDR, Doctor of Pharmacy, Peptide, Multimedia, Bystander effect, Neoplasm, Medicine, DXD, NMS, Doctor of Philosophy, PDC, Fine chemical, Vaccine, Trastuzumab deruxtecan

(NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

Key Points: 
  • (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).
  • View the full release here: https://www.businesswire.com/news/home/20231214543204/en/
    Under the terms of the agreement, ITF will use NMS’s proprietary linker-payload technology to develop a novel PDC product candidate.
  • This is a significant step to broaden the applicability of our technology,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS and NMS Group.
  • The development program will leverage NMS’s proprietary innovative linker-payload platform technology and ITF’s peptide-based oncology therapeutics technology.

MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 7, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, MMAE, MBrace, Safety, Research and development, New Jersey Medical School, Spacecraft, Therapy, Annexin A5, Immunoglobulin G, ADC, HED, Breast cancer, Teaching hospital, Patient, TNBC, Division, Laboratory, Breast, Cancer, Professor, Cell, Cooper University Hospital, HR, Medical imaging

MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

Key Points: 
  • MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.
  • In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples.
  • EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.
  • Details of the poster presentation are as follows:
    Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CR, Rat, Neoplasm, Patient, Pneumonitis, Ovarian cancer, PDT, Trae tha Truth, MPH, Therapy, Endometrial cancer, Pharmacokinetics, Safety, Conjugation, PTK7, MMAE, SITC, Immunotherapy, SD, Bone marrow, ADC, Spacecraft, Breast cancer, Mesothelioma, Lung cancer, Society, Cancer, Cytopenia, Therapeutic index, Fatigue, Fine chemical, Medical imaging, Vaccine, Pharmaceutical industry, Communications satellite, Part

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Key Points: 
  • ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).
  • “We are thrilled to present proof-of-concept data from our novel sesutecan ADC platform with the initial clinical results for Rina-S,” said ProfoundBio Chief Medical Officer Naomi Hunder, M.D.
  • Enrolled patients had the following tumor types: ovarian cancer (n=17), endometrial cancer (n=9), breast cancer (n=3), non-small cell lung cancer (n=5), and mesothelioma (n=2).
  • Superior tumor growth inhibition and tolerability relative to the precedent PTK7-directed ADC cofetuzumab pelidotin were observed in head-to-head preclinical studies.

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Retrieved on: 
Monday, October 16, 2023
CSPC, Plasma, AACR, Cancer, Half-life, EV, Therapy, MMAE, ADC, Conference, Patient, Poster, Sun, Vaccine

A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic.

Key Points: 
  • A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic.
  • CRB-701 demonstrates statistically significant tumor growth inhibition in preclinical models that express mid- and high-levels of nectin-4, similar to EV.
  • CRB-701 has a longer half-life than EV and is being dosed on a Q3W schedule in the clinic.
  • “We are excited to share for the first time the pre-clinical validation of CRB-701 that supports its exploration in the clinic.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Saturday, June 3, 2023
Pancreatic cancer, CT, PRS, MMAE, Neoplasm, DCR, American Society of Clinical Oncology, RECIST, Trae Elston, CSPC, Shijiazhuang Pharma Group, ASCO, ORR, Publication, Patient, Cancer, Annual general meeting, Mab, ADC, Financial toxicity, DAR, Stomach, Society, SD, Pharmaceutical industry, Vaccine, Medical imaging

NEW YORK, June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Key Points: 
  • These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
  • Elevation Oncology's partner, CSPC, is actively recruiting patients in the Phase 1 clinical trial of SYSA1801 (EO-3021) in China (NCT05009966).
  • "While the study remains ongoing, the responses seen are particularly impressive, especially in the gastric cancer setting in tumors expressing Claudin 18.2.
  • These results are highly informative as Elevation Oncology prepares to initiate a Phase 1 clinical trial of EO-3021 in the US in the second half of 2023."